- Annual Report 2012(1,945KB) (PDF File)
- Cover / Becoming a "Company that Can Continue to Provide New Value" （215KB）
- Message from the President（155KB）
- Profile（101KB）
- Financial Highlights（47KB）
- Interview with the President
To Be a Global Research-driven Pharmaceutical Company that is Trusted by Communities（289KB） - Special Features - Value Creation Business Model
CASE STUDY 1: Business Model at the Drug Discovery Stage
CASE STUDY 2: Business Model at the Post-marketing Development Stage（269KB） - Overview of Medium-Term Management Plan 11-15（130KB）
- State of New Product Development（87KB）
- Overview of Core Ethical Drugs and Sales Trends（148KB）
- Corporate Social Responsibility（73KB）
- Corporate Governance and Internal Control（79KB）
- Board of Directors and Auditors（81KB）
- Financial Section（757KB）
- Six-Year Financial Summary（37KB）
- Management's Discussion and Analysis（81KB）
- Operational Risks（41KB）
- Consolidated Balance Sheets（39KB）
- Consolidated Statements of Income（31KB）
- Consolidated Statement of Comprehensive Income（28KB）
- Consolidated Statements of Changes in Net Assets（32KB）
- Consolidated Statements of Cash Flows（35KB）
- Notes to Consolidated Financial Statements（142KB）
- Report of Independent Auditors（22KB）
- Group Companies（35KB）
- Corporate Data / Investor Information（71KB）
